The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA

Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA

October 15, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Zilretta Promising in Phase 2 Trial
Zilretta (triamcinolone acetonide extended release) is an intra-articular injection for managing osteoarthritis (OA) knee pain. A Phase 2 study of the treatment examined blood glucose levels in patients with type 2 diabetes and OA knee pain.1

You Might Also Like
  • Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
  • Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial
  • FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
Also By This Author
  • Tigulixostat Appears Promising for the Treatment of Gout

 During the double blind, randomized study, data showed that patient’s blood glucose levels were significantly lower after administration of Zilretta compared with those in patients treated with an injection of immediate release triamcinolone acetonide in crystalline suspension (TAcs). Blood glucose levels were measured 72 hours prior to injection through 72 hours after the injection. Adverse event rates were low and similar between treatment groups. Adverse events were all Grade 1 or 2, and no Zilretta-treated patients experienced an index-knee or injection-related adverse event.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Zilretta is not intended for repeat administration. The treatment was approved by the U.S. Food and Drug Administration as the first extended release intra-articular injection for OA. Its formulation combines triamcinolone acetonide with a poly lactic-co-glycolic acid (PLGA) matrix that provides pain relief for more than 12 weeks.

Filgotinib Promising for RA in Phase 3 Trial
Filgotinib, a selective JAK1 inhibitor, has met the primary endpoint and all key secondary endpoints in its first Phase 3 study for rheumatoid arthritis (RA). This study (FINCH 2) was a global, randomized, placebo-controlled study in adults with moderate to severe, active RA with prior intolerance or inadequate response to biologic agents.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the study, the primary endpoint was the proportion of patients who achieved an ACR20 response at Week 12. Key secondary endpoints included the proportion of patients achieving ACR50 and ACR70, as well as the proportion of patients achieving low disease activity and clinical remission at Weeks 12 and 24. Patients received either 100 mg filgotinib once daily, 200 mg filgotinib once daily or placebo.

All primary and secondary endpoints were significantly higher for filgotinib-treated patients compared with placebo-treated patients. Overall, filgotinib was generally well tolerated with no new safety signals identified. During the study, two major adverse cardiovascular events occurred, as well as one subarachnoid hemorrhage in a placebo-treated patient and one myocardial ischemia in a 100 mg filgotinib-treated patient.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Flexion Therapeutics Inc. News release: Flexion Therapeutics announces publication of phase 2 diabetes data in September issue of Rheumatology. 2018 Sep 10.
  2. Gilead. News release: Gilead and Galapagos announce filgotinib meets primary and all key secondary endpoints in first phase 3 study in rheumatoid arthritis. 2018 Sep 11.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Biologics & Biosimilars, Drug Updates Tagged With: blood glucose, filgotinib, Knee Osteoarthritis (OA), knee pain, Rheumatoid Arthritis (RA), Zilretta

You Might Also Like:
  • Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
  • Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial
  • FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
  • IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)